Stroke 11 items
Studies
- Drug-target Mendelian randomization finds genetically proxied CETP inhibition protects against subarachnoid hemorrhage with no safety signal (Eur Stroke J 2025)
- CETP variants that raise HDL cholesterol also increase risk of intracerebral haemorrhage (Ann Neurol 2016)
- Genetic variants at the CETP inhibitor target show split effects on ischaemic small vessel stroke and brain haemorrhage (Brain 2020)
- Mendelian randomisation suggests genetically proxied CETP inhibition may lower intracranial aneurysm risk (Neurosurg Rev 2026)
- Mendelian randomization links CETP inhibition to lower lacunar stroke risk via cerebral small vessel disease genetics (Brain 2025)
- Mendelian randomization finds genetically raised HDL via CETP predicted to lower small vessel stroke risk (J Am Heart Assoc 2024)
- CETP I405V variant shows a strong, first-reported association with ischemic stroke risk in a Caucasian population (J Stroke Cerebrovasc Dis 2018)
- Meta-analysis confirms the CETP TaqIB B2 allele protects against ischemic stroke (J Stroke Cerebrovasc Dis 2017)
- CETP Taq1 B2 allele nearly halves ischemic stroke risk in Sardinian women, but not men (J Intern Med 2007)
- Review proposes probucol as an alternative stroke-prevention therapy for patients at high haemorrhage risk (Brain Circ 2023)
- CETP TaqIB genotype shows no link to plaque composition or neointima after carotid endarterectomy, unlike hepatic lipase variant (Atherosclerosis 2005)